Roche pulls another major piece out of the wobbly Alzheimer's jenga, shuttering crenezumab PhIIIs
When AC Immune announced two years ago that its partners at Genentech is launching a second Phase III for its Alzheimer’s drug, CEO Andrew Pfeifer touted crenezumab as a “distinct” hope amid disappointing results of other anti-amyloid beta therapies, given at higher doses and targeting earlier stages of the disease.
Today crenezumab has become a big disappointment itself — marking another prominent failure in a frustration-prone field.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.